Anti-inflammatory and neuroprotective effects of sanguinarine following cerebral ischemia in rats

QIN WANG, PENG DAI, HAN BAO, PING LIANG, WEI WANG, AN XING and JIANBIN SUN

State Key Laboratory of Cancer Biology, Department of Pharmacogenomics, School of Pharmacy, The Fourth Military Medical University, Xi’an, Shaanxi 710032, P.R. China

Received December 15, 2015; Accepted February 25, 2016

DOI: 10.3892/etm.2016.3947

Abstract. Stroke is one of the leading causes of mortality worldwide. Protective agents that can diminish injuries caused by cerebral ischemia-reperfusion (I/R) are important in alleviating the harmful outcomes of stroke. The aim of the present study was to investigate the protective role of sanguinarine in cerebral I/R injury. A rat middle cerebral artery occlusion model was used to assess the clinical effect of sanguinarine, and inflammatory cytokines in the serum were detected by ELISA. Western blotting was performed to examine the change in levels of apoptosis-associated proteins in the injured brains. The results suggested that sanguinarine, an anti-inflammatory agent derived from the roots of Sanguinaria canadensis, improved the state of cerebral ischemia in a rat model. The data demonstrated that when rats were treated with sanguinarine prior to middle cerebral artery occlusion, the infarct volume was reduced significantly. The inflammatory factors tumor necrosis factor-α, interleukin (IL)-6 and IL-1β were measured in sanguinarine and vehicle-treated groups using an enzyme-linked immunosorbent assay, and the expression levels of the three factors were significantly reduced following treatment with sanguinarine (P<0.05). In addition, western blot analysis demonstrated that the ratio of B-cell lymphoma 2/Bcl-2-associated X protein was significantly increased following treatment with sanguinarine (P<0.05). The study demonstrated that sanguinarine exerts a protective effect in cerebral ischemia, and that this effect is associated with the anti-inflammatory and anti-apoptotic properties of sanguinarine.

Introduction

Sanguinarine, with a formula of 13-methyl-[1,3]benzodioxolo[5,6-c]-1,3-dioxolo[4,5-i]phenanthridinium, is an active ingredient derived from the roots of Sanguinaria canadensis, the seeds of Argemone mexicana and from various other poppy-fumaria species (1,2). Sanguinarine is of great interest from a practical and research perspective due to its widespread and evident biological activities (3). It is used as a naturopathic therapy for treating infections and managing pain, and as an expectorant, sedative and emetic (3). Sanguinarine has been demonstrated to exhibit anti-oxidant, anti-tumor, anti-inflammatory and anti-microbial properties (1,4-7). However, the effect of sanguinarine on neuroprotection has not been widely investigated.

Stroke or cerebral ischemia is one of the leading causes of long-term disabilities and mortality worldwide. Ischemic injury is caused by a permanent or transient reduction in cerebral blood flow in the brain artery (8,9). As a result of oxygen depletion, brain tissue is exposed to a dramatic decline in blood flow, Ca²⁺ overload, mitochondrial and DNA damage, excessive glutamate-receptor activation and oxygen radical formation (8,9). Necrosis and apoptosis then occur in brain cells, leading to eventual cell death. Various mechanisms of cerebral ischemia have been identified in previous studies, including excitotoxicity, peri-infarct depolarizations, inflammation and programmed cell death (10,11). Following ischemia, inflammatory cells (including microglia and blood-derived leukocytes) are activated and accumulate in the brain tissue, resulting in inflammatory injury.

During the processes of cerebral ischemia or stroke, certain molecular factors are generated, which then activate components of innate immunity, promote inflammatory signaling and cause tissue damage (12). The most extensively studied inflammatory cytokines associated with stroke include interleukin (IL)-1β, IL-6, IL-10 and tumor necrosis factor-α (TNF-α). These molecules gather more leukocytes to the site of ischemia, resulting in further loss of nerve cells, increased apoptosis or necrosis in cerebral tissue, and an increased area of cerebral infarction (13). All these functions are considered to induce apoptosis. Members of the B-cell lymphoma 2 (Bcl-2) family serve an important role in cerebral ischemia. In particular, Bcl-2 (which is an anti-apoptotic protein) and Bcl-2-associated X protein (Bax; which is a pro-apoptotic...
protein) regulate apoptosis by mutual suppression (14). Shortly following the beginning of ischemia, dephosphorylation and translocation of Bax from the cytosol to the mitochondria, as well as dimerization of Bax with antiapoptotic proteins, occur in the brain (15,16). Bax is then oligomerized and activated, eventually triggering the release of apoptotic proteins stored in the mitochondrial intermembrane space, resulting in neuronal apoptosis (17).

Considering that inflammatory changes occur during the acute phase of ischemic stroke, and that inflammation serves a central role in the disease outcome, the use of anti-inflammatory treatment agents may benefit patients suffering an ischemic stroke. Thus, the development of anti-inflammatory drugs is required for the recovery from stroke. Sanguinarine is known to be an effective, naturally active, anti-inflammatory agent. Therefore, the current report investigated the in vivo effect of sanguinarine treatment in an animal model of middle cerebral artery occlusion (MCAO). The findings provide an insight into the sanguinarine-dependent anti-inflammatory and anti-apoptotic activities in brain injury.

Materials and methods

Animals. A total of 24 male adult Sprague-Dawley rats (age, 8-10 weeks; weight, 240-260 g) were provided by the Lab Animal Center of The Fourth Military Medical University (Xi’an, China) and housed in polypropylene cages in an air-conditioned room (24˚C, 50% humidity) with a 12-h dark:light cycle, allowing free access to pelleted diet and water. There were three groups in total, each with 8 rats. All experiments were performed in accordance with the Guidelines for Animal Research of The Fourth Military Medical University. The study was approved by the Ethics Committee of Medical Ethics and the Human Clinical Trial Committee of Xijing Hospital (approval no. XJYYLL-2015694).

Reagents. Sanguinarine was purchased from Shaanxi Huike Botanical Development Co., Ltd (Xi’an, China). Triphenyl tetrazolium chloride (TTC) was purchased from Amresco, LLC (Solon, OH, USA) and was dissolved in phosphate buffered saline (PBS) at 1% (m/v). All ELISA kits for IL-1β (cat no. CSB-E08055r), IL-6 (cat no. CSB-E04640r) and TNF-α (cat no. CSB-E11987r) were purchased from Cusabio Biotech Co., Ltd. (Wuhan, China). All antibodies were purchased from Proteintech (Wuhan, China). The enhanced chemiluminescence kit was purchased from EMD Millipore (cat no. WBKLS0100; Billerica, MA, USA).

MCAO animal model. The MCAO model was established in male Sprague-Dawley rats as previously described (18,19). Rats were anesthetized using 10% chloral hydrate (Dalian Meilun Biotech Co., Ltd., Dalian, China) throughout the surgery. MCAO was maintained for 2 h, followed by reperfusion for 24 h (20). Sanguinarine was suspended in 0.5% carboxymethyl cellulose (CMC)-Na (Tianguan, Guangzhou, China) and rats were administered a dose of 15 mg/kg intragastrically. For the vehicle-treated group, equal volumes of 0.5% CMC-Na were administered. In the vehicle-treated group, the same volume of 0.5% CMC-Na was administered 1 h prior to MCAO. Rats were anesthetized with chloral hydrate and decapitated 24 h after MCAO.

Neurological evaluation. Modified neurological severity score (mNSS) was determined 1 day after MCAO by two independent observers. All assessments were performed in triplicate. This scoring included evaluation of the balance, sensory, reflex and motor of rats, and scores were graded on a scale of 0-18 (21). A higher score represents a more severe injury (normal = 0; maximal deficit = 18).

Measurement of infarct volume. Rats were anesthetized with 10% chloral hydrate and decapitated following reperfusion for 24 h. Brains were rapidly and carefully removed, and sliced into 2-mm continuous slices using a metallic brain matrix (Xinruan Information Technology Co. Ltd., Shanghai, China). The slices were stained with 1% TTC at 37˚C for 15 min in the dark, then fixed with 4% formaldehyde in PBS. The unstained waxy area of the brain slice was defined as infarction, and the infarct volume ratio was measured and calculated as described previously (22).

Nissl stain of rat brain. The rats treated by ischemia reperfusion after MCAO and sustained for 24 h, then anesthetized with 10% chloral hydrate, and processed by transcardial perfusion with PBS and then with 10% neutral-buffered formalin. Next, the brains were removed and immersed in 10% fresh neutral-buffered formalin for 24 h and embedded in paraffin. The brains were then cut into 2 mm thick sections, dewaxed, rehydrated with xylene and ethanol and stained with 0.5% (m/v) Toluidine Blue (Sigma-Aldrich, St. Louis, MO, USA). Nissl bodies were visualized with an Eclipse Ti-U Inverted Microscope System (Nikon Corporation, Tokyo, Japan) and counted using Image-Pro Plus version 6.0 (Media Cybernetics, Inc., Rockville, MD, USA).

ELISA of TNF-α, IL-6 and IL-1β. The injured areas of the brain tissue were removed 24 h after ischemia/reperfusion (I/R) injury, washed in cold PBS and placed into a homogenate tube. Appropriate volume of PBS were added into the tubes at 4˚C, to allow for the tissues to be ground into 10% homogenate. The supernatant was collected following centrifugation at 4,000 x g for 15 min. The protein levels of TNF-α (cat no. CSB-E11987r), IL-6 (cat no. CSB-E04640r) and IL-1β (cat no. CSB-E08055r) were determined using ELISA kits (Cusabio Biotech Co., Ltd.) according to the manufacturer's instructions, which included the addition of 100 µl of appropriately diluted samples to each well. Standards (triplicates) and blanks were run with each plate to ensure accuracy.

Western blotting assay. The injured area of the brain tissue was homogenized in cold radioimmunoprecipitation assay buffer (Sigma-Aldrich). The concentrations of whole cell extracts were determined by bicinechonic acid assay (Thermo Fisher Scientific, Inc., Waltham, MA, USA) and 20 µg total proteins were loaded into each well. Protein extracts were subjected to electrophoresis on a 10% Bis-Tris protein gel (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA). The membranes were incubated with the following primary
induced by cerebral ischemia results in an increase in the expression of inflammatory proteins (26). Cytokines can activate the cerebrovascular endothelium and glial cells in the brain and affect ischemic brain injury (27,28). Among the large number of cytokines, TNF-α, IL-1β, IL-6 and IL-1β modulate tissue injury in stroke, and are therefore potential targets in developing treatments for stroke (29). The effect of cytokines on the extent of infarction depends on their viability in ischemic penumbra during the early phase of stroke (28). Numerous neuroprotective agents have been found to be effective in animal models of stroke; however, few studies have translated these findings into clinical applications. One reason for this may be the failure to consider clinical co-morbidities and risk factors in experimental animal models (27).

As an efficient anti-inflammatory agent, sanguinarine has been used for centuries as a therapeutic agent for the treatment of inflammatory diseases (1); however, the protective effect of sanguinarine on cerebral ischemia is poorly reported. In the present study, the effect of sanguinarine on cerebral ischemia was examined, and its therapeutic action was investigated in a well-controlled animal model of MCAO. The results demonstrated that pre-treatment with sanguinarine prevents delayed neuronal death in the MCAO model. In addition, it was observed that pre-treatment with sanguinarine was neuroprotective in transient cerebral ischemia in rats, as the infarct volume of MCAO rats was found to be significantly reduced in the sanguinarine-treated group. The injury of neurons following MCAO was found to be significantly lower in sanguinarine-treated rats (15.03%), when compared with the sham group (189.33 ± 29.41 vs. 506.00 ± 30.83, respectively; P < 0.01; Fig. 2). Treatment with sanguinarine significantly increased the reduced neuronal cell death (328.00 ± 45.77) when compared with that in the vehicle-treated rats (189.33 ± 29.41; P < 0.05).

Sanguinarine reduces inflammatory cytokine expression. Ischemic injury results in cerebric lesion; however, the mechanisms underlying this process are poorly understood (23). The central nervous immune system interact in complex ways. The destruction of neurons induced by cerebral ischemia results in an immune response that is necessary to remove cell debris and initiate the regenerative process; however, this inflammatory response can aggravate cerebral damage and cause secondary cerebral injuries (24,25). Circulating inflammatory mediators can activate the cerebrovascular endothelium and glial cells in the brain and affect ischemic brain injury (26). Cytokines are important inflammatory mediators (27,28) and their role has been well established in previous in vivo and in vitro investigations. Ischemic injury results in an increase in the release of cytokines, which are involved in the necrosis of neuronal cells (27,28). Among the large number of cytokines, TNF-α, IL-1β and IL-6 modulate tissue injury in stroke, and are therefore potential targets in developing treatments for stroke (29). The effect of cytokines on the extent of infarction depends on their viability in ischemic penumbra during the early phase of stroke (28). Numerous neuroprotective agents have been found to be effective in animal models of stroke; however, few studies have translated these findings into clinical applications. One reason for this may be the failure to consider clinical co-morbidities and risk factors in experimental animal models (27).

Discussion

Inflammation is a pathological marker of ischemic stroke and results in cerebral lesion; however, the mechanisms underlying this process are poorly understood (23). The central nervous and immune system interact in complex ways. The destruction of neurons induced by cerebral ischemia results in an immune response that is necessary to remove cell debris and initiate the regenerative process; however, this inflammatory response can aggravate cerebral damage and cause secondary cerebral injuries (24,25). Circulating inflammatory mediators can activate the cerebrovascular endothelium and glial cells in the brain and affect ischemic brain injury (26). Cytokines are important inflammatory mediators (27,28) and their role has been well established in previous in vivo and in vitro investigations. Ischemic injury results in an increase in the release of cytokines, which are involved in the necrosis of neuronal cells (27,28). Among the large number of cytokines, TNF-α, IL-1β and IL-6 modulate tissue injury in stroke, and are therefore potential targets in developing treatments for stroke (29). The effect of cytokines on the extent of infarction depends on their viability in ischemic penumbra during the early phase of stroke (28). Numerous neuroprotective agents have been found to be effective in animal models of stroke; however, few studies have translated these findings into clinical applications. One reason for this may be the failure to consider clinical co-morbidities and risk factors in experimental animal models (27).

As an efficient anti-inflammatory agent, sanguinarine has been used for centuries as a therapeutic agent for the treatment of inflammatory diseases (1); however, the protective effect of sanguinarine on cerebral ischemia is poorly reported. In the present study, the effect of sanguinarine on cerebral ischemia was examined, and its therapeutic action was investigated in a well-controlled animal model of MCAO. The results demonstrated that pre-treatment with sanguinarine prevents delayed neuronal death in the MCAO model. In addition, it was observed that pre-treatment with sanguinarine was neuroprotective in transient cerebral ischemia in rats, as the infarct volume of MCAO rats was found to be significantly reduced in the sanguinarine-treated group. The injury of
brain structure was also declined in the sanguinarine-treated group.

The mechanism of action of sanguinarine was also investigated in the present study. The results demonstrated that treatment with 15 mg/kg sanguinarine resulted in a significant reduction in cerebral infarction in MCAO-induced rats with permanent focal cerebral ischemia. In addition, sanguinarine exerted neuroprotective effects against histological injury and neurological deficits following ischemia. The expression of Bcl-2 increased, while that of Bax was reduced, and the

Figure 1. (A) TTC staining of the brains of rats from each group after 24 h of reperfusion. (B) Quantification of TTC staining. The infraction volume decreased significantly when rats were administrated SANG (15 mg/kg) prior to middle cerebral artery occlusion. Data are presented as the mean ± standard error, n=8. *P<0.05 vs. the vehicle group. TTC, triphenyl tetrazolium chloride; SANG, sanguinarine.

Figure 2. Nissl staining of the (A) sham (B) vehicle-treated and (C) SANG-treated groups (magnification, x100). (D) Quantification of Nissl-positive cells in the cortex. Treatment with SANG significantly increased the numbers of Nissl bodies in comparison with the vehicle-treated rats. Values are presented as the mean ± standard error, n=8. *P<0.05 and **P<0.001 vs. the vehicle group. SANG, sanguinarine.
release of inflammatory cytokines TNF-α, IL-1β and IL-6 was reduced following pre-treatment with sanguinarine.

In conclusion, the present study demonstrated that sanguinarine treatment mediated a significant protective effect in vivo. The results suggested that sanguinarine effectively reduced apoptosis in brain cells following sanguinarine treatment, since the pro-apoptotic Bax was downregulated and the anti-apoptotic Bcl-2 was upregulated. The current study contributes towards the understanding of the protective properties of sanguinarine in MCAO animal models and the molecular mechanisms underlying this activity. Thus, to the
best of our knowledge, this study provided the first scientific support for the use of sanguinarine for the treatment of human cerebral ischemia disease.

References


